Pharvaris Netherlands B.V.

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Pharvaris Netherlands B.V. sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 2 currently recruiting 3 completed later-stage tilt upper quartile by trial count

Pharvaris Netherlands B.V.: 6 sponsored US clinical trials, 2 recruiting.

Pharvaris Netherlands B.V. sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 4 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hereditary Angioedema (HAE), with 2 trials.

Upper-quartile sponsor footprint

Pharvaris Netherlands B.V. sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 3

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

NCT07266805
RECRUITING Phase 3

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06679881
ACTIVE NOT RECRUITING Phase 3

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06669754
COMPLETED Phase 3

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT06343779
COMPLETED Phase 2

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

NCT05047185
COMPLETED Phase 2

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT04618211

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 4

Therapeutic Areas

Hereditary Angioedema (HAE) 2
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) 1

Where Pharvaris Netherlands B.V. enrollment is open (later-stage tilt)

2 recruiting of 6 indexed (33% open); 3 completed (50%).

Phase mix: 4 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Hereditary Angioedema (HAE) (2 trials), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Pharvaris Netherlands B.V.: open-pipeline peers nationwide

Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Pharvaris Netherlands B.V. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%20%40%60%80% Total trials Recruiting share Pharvaris Netherlands B.V.23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchAadi BioscienceAaron CookAbivax S.A.Actuated Medical
Pharvaris Netherlands B.V. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pharvaris Netherlands B.V. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Pharvaris Netherlands B.V. page

6 registered trials is a research-attention snapshot, not an endorsement of Pharvaris Netherlands B.V. or any single study.

  • 2 of Pharvaris Netherlands B.V.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hereditary Angioedema (HAE) is the condition Pharvaris Netherlands B.V. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hereditary Angioedema (HAE) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Pharvaris Netherlands B.V. pipeline card: 6 registered trials from official public datasets.Report a data error.